Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
08/2000
08/02/2000EP1023897A2 Dermal agent
08/02/2000EP1023896A2 Opioid formulations for treating pain
08/02/2000EP1023445A1 Cadherin derived growth factor and the application thereof
08/02/2000EP1023444A1 Cell division regulators
08/02/2000EP1023441A1 Models and treatments for cardiac hypertrophy in relation with nf-at3 function
08/02/2000EP1023323A1 Novel vitamin d receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof
08/02/2000EP1023313A1 Inhibition of stress activated protein kinase (sapk) pathway and sensitization of cells to cancer therapies
08/02/2000EP1023312A1 Method for modulating gene expression
08/02/2000EP1023311A1 Novel bacterial polypeptides and polynucleotides
08/02/2000EP1023284A2 Anti-viral pharmaceutical compositions containing saturated 1,2-dithiaheterocyclic compounds and uses thereof
08/02/2000EP1023281A1 Hiv integrase inhibitors
08/02/2000EP1023081A1 Use of recombinant human uteroglobin in treatment of inflammatory and fibrotic conditions
08/02/2000EP1023074A1 Methods for treating psychosis associated with glucocorticoid related dysfunction
08/02/2000EP1023072A1 Analgesic compositions
08/02/2000EP1023069A1 Nicotine compositions and methods of formulation thereof
08/02/2000EP1023067A2 The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
08/02/2000EP1023060A1 UPREGULATION OF TYPE III ENDOTHELIAL CELL NITRIC OXIDE SYNTHASE BY HMG-CoA REDUCTASE INHIBITORS
08/02/2000EP1023057A1 Use of thiazolidinediones for the treatment of hyperglycaemia
08/02/2000EP1023056A1 Use of thiazolidinediones for the treatment of hyperglycaemia
08/02/2000EP1023049A1 Preparation of a directly mouldable tabletting auxiliary
08/02/2000EP1023040A1 Compositions based on plant extracts
08/02/2000EP1022951A1 Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
08/02/2000EP1022945A2 Method and formulation for treating vascular disease
08/02/2000EP0748222B1 Antitussive composition containing an antitussive and benzydamine
08/02/2000CN1261810A Method of screening compounds useful for prevention of infection or pathogenicity
08/02/2000CN1261804A Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor
08/02/2000CN1261803A Antioxidant enhancement of therapy for hyperproliferative conditions
08/02/2000CN1261801A Allelic polygene diagnosis of reward deficiency syndrome and treatment
08/02/2000CN1261791A Targeted liposomal constructs for diagnostic and therapeutic uses
08/02/2000CN1261541A Anti-tumor biological product and preparing method
08/01/2000US6096787 Use of selective ligands for treatment of disease states responsive to steroid or steroid-like hormones
08/01/2000US6096785 Administering glycine to the human patient for treating renal dysfunction induced by cyclosporins or ascomycins
08/01/2000US6096780 Antiviral compound useful for treating hiv viruses
08/01/2000US6096777 Method for inhibiting the expression of Fas
08/01/2000US6096739 Treatment for CNS injuries
08/01/2000US6096737 Treatment of multiple sclerosis (MS) and other demyelinating conditions using lofepramine in combination with L-phenylalanine, tyrosine or tryptophan and possibly a vitamin B12 compound
08/01/2000US6096729 Use of NK-1 receptor antagonists for treating amnestic disorders
08/01/2000US6096726 Multicomponent complex for use with substrate
08/01/2000US6096517 Human kidney sodium bicarbonate transporter (HNBC1A) polynucleotides
08/01/2000CA2189250C Cytokine regulatory agents and methods of use in pathologies and conditions associated with altered cytokine levels
08/01/2000CA2133762C Synergistic combination of a substance with gastric acid secretion inhibiting effect and an acid degradable antibiotic
08/01/2000CA2117265C Enhanced skin penetration system for improved topical delivery of drugs
08/01/2000CA2026036C Sulphated glycosamino glycuronan with antithrombotic activity
07/2000
07/29/2000CA2290771A1 Azithromycin combination for emesis control in dogs
07/27/2000WO2000043790A2 Compositions and methods for the diagnosis and treatment of tumor
07/27/2000WO2000043781A2 Growth differentiation factor inhibitors and uses therefor
07/27/2000WO2000043553A1 Identifying, monitoring, and treating women for breast precancer or cancer
07/27/2000WO2000043524A1 Polypeptides derived from jnk3
07/27/2000WO2000043511A1 Polypeptide
07/27/2000WO2000043501A2 Ribozymes directed against the catalytic subunit of the human telomerase (htert)
07/27/2000WO2000043495A2 33 human secreted proteins
07/27/2000WO2000043419A2 Exocytosis pathway proteins and methods of use
07/27/2000WO2000043405A1 Bis-terpyridine-platinum(ii) complexes
07/27/2000WO2000043038A1 Methods and devices for delivery of agents to breast milk ducts
07/27/2000WO2000043032A2 Baff, inhibitors thereof and their use in the modulation of b-cell response
07/27/2000WO2000043031A1 Tumor necrosis factor antagonists and their use in endometriosis
07/27/2000WO2000043030A1 Method of suppressing ongoing acute allograff rejection
07/27/2000WO2000043028A2 Method of treating chronic cardiac disease
07/27/2000WO2000043014A2 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections
07/27/2000WO2000043008A1 Anti-androgens and methods for treating disease
07/27/2000WO2000042989A2 Novel hydrogel isolated cochleate formulations, process of preparation and their use for the delivery of biologically relevant molecules
07/27/2000WO2000042987A2 Targeted vesicular constructs for cytoprotection and treatment of h. pylori infections
07/27/2000WO2000042976A1 Cosmetics
07/27/2000WO2000042955A1 Drug dosage unit for buccal administration of steroidal active agents
07/27/2000WO2000042841A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
07/27/2000WO2000042832A2 New compounds for the treatment of cancer
07/27/2000WO2000028980A3 Combination of duloxetine with non-steroidal antiinflammatory drug for treating pain
07/27/2000WO2000027897A3 Silane copolymer coatings
07/27/2000WO2000025723A3 Methods and compositions for the prevention of tolerance to medications
07/27/2000WO2000023618B1 Polymorphism in a tgf-beta gene correlated to osteoporosis
07/27/2000WO2000023096A3 Combination therapy with vip antagonist
07/27/2000WO2000023086A3 Buffered compositions for dialysis
07/27/2000WO2000023062A3 Irrigation solution and method for inhibition of pain and inflammation
07/27/2000WO2000023057A3 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition
07/27/2000WO2000018915A3 Membrane-associated organizational proteins
07/27/2000WO2000011171A3 Human rna-associated proteins
07/27/2000WO2000004157A3 Cloning and characterisation of novel mammalian peptidases
07/27/2000WO2000003743A9 Use of inhibitors of prenyltransferases for inhibiting fungal growth
07/27/2000WO1999066944A9 Methods for identifying novel multimeric agents that modulate receptors
07/27/2000WO1999055322A9 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
07/27/2000DE10003356A1 Novel ribozymes targeted against the catalytic subunit of the human telomerase enzyme reverse transcriptase are useful for treating tumors
07/27/2000CA2361272A1 33 human secreted proteins
07/27/2000CA2361123A1 Methods for identifying, treating or monitoring asymptomatic patients for risk reduction or therapeutic treatment of breast cancer
07/27/2000CA2361122A1 Methods and devices for delivery of agents to breast milk ducts
07/27/2000CA2360908A1 Bis-terpyridine-platinum(ii) complexes
07/27/2000CA2360062A1 Baff, inhibitors thereof and their use in the modulation of b-cell response
07/27/2000CA2359681A1 Method of treating chronic cardiac disease
07/27/2000CA2359587A1 Compact dosage unit for buccal administration of steroidal active agent
07/27/2000CA2359145A1 Exocytosis pathway proteins and methods of use
07/27/2000CA2358971A1 Identifying, monitoring, and treating women for breast precancer or cancer
07/27/2000CA2358963A1 Cancer-associated proteins
07/27/2000CA2358914A1 Polypeptides derived from jnk3
07/27/2000CA2358899A1 Polypeptide
07/27/2000CA2354375A1 Compositions and methods for the diagnosis and treatment of tumor
07/26/2000EP1022029A1 Nootropic agent
07/26/2000EP1022027A1 Tumor necrosis factor antagonists and their use in endometriosis
07/26/2000EP1021543A1 Mutants of yeast cdc24p, defective in binding of the g-protein beta subunit
07/26/2000EP1021540A1 Human progesterone receptor complex p23-like protein
07/26/2000EP1021539A1 A method for selectively controlling membrane protein display and protein secretion in eukaryotic cells
07/26/2000EP1021536A2 Mammalian genes involved in viral infection and tumor suppression
1 ... 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 ... 1151